New cell therapy JY231 targets tough leukemia in early human test
NCT ID NCT06514768
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study is testing a new treatment called JY231 for people with B-cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer. The main goal is to check if JY231 is safe and tolerable, and to see if it can help control the disease. About 20 adults and children up to age 75 will take part. The treatment uses specially designed cells to target and attack cancer cells that have a marker called CD19.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
920th HJointLogistics
RECRUITINGKunming, Yunnan, China